drugset / Trial / NCT02601612
Safety and Immunogenicity of the RSV D46cpΔM2-2 Vaccine in RSV-Seropositive Children and RSV-Seronegative Infants and Children
RandomizedParallel-groupQuadruple-blindPrevention
Summary
The purpose of this study is to evaluate the safety and immunogenicity of the RSV D46cpΔM2-2 vaccine in RSV-seropositive children and RSV-seronegative infants and children.
Timeline
- Start
- 2015-10
- Primary completion
- 2018-04-26
- Completion
- 2018-04-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | D46cpΔM2-2 | Vaccine | 100000 unknown | Intranasal |
| Subject | D46cpΔM2-2 | Vaccine | 1e+06 unknown | Intranasal |